Solid Organ Transplant
20
3
5
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.0%
1 terminated out of 20 trials
91.7%
+5.2% vs benchmark
15%
3 trials in Phase 3/4
18%
2 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (20)
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients
Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients
Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients
iParent2Parent Program for Parents of Pediatric Solid Organ Transplant Recipients
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
iPeer2Peer Pediatric Thoracic Transplantation
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
REmote moBile Outpatient mOnitoring in Transplant 2.0
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
Early Flu Shots in SOT
Discharge to Home and Chronic Illness Care Pilot
Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection
Bortezomib Plus Rituximab for EBV+ PTLD
Transition From Hospital to Home in Solid Organ Transplant (SOT)
Fusariosis in Solid-Organ Transplant Recipients